Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

in response to

Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

narmac

posted on Jan 30, 2019 07:36AM

That’s a big deal for a preclinical blood cancer drug , i am guessing that is going to benchmark a Zenith potential deal for Zen 3694 , any less would be unacceptable as we are nearing a phase 2 trial

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply